Clinical Trial Detail

NCT ID NCT03056755
Title Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (BYLieve)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals

Her2-receptor negative breast cancer


Alpelisib + Fulvestrant

Alpelisib + Letrozole

Age Groups: adult senior

Additional content available in CKB BOOST